Last reviewed · How we verify

metformin 0.85 twice daily for 6 months — Competitive Intelligence Brief

metformin 0.85 twice daily for 6 months (metformin 0.85 twice daily for 6 months) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

marketed Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

metformin 0.85 twice daily for 6 months (metformin 0.85 twice daily for 6 months) — Xiang Guang-da. Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, lowering blood glucose levels in type 2 diabetes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
metformin 0.85 twice daily for 6 months TARGET metformin 0.85 twice daily for 6 months Xiang Guang-da marketed Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
metformin+ gliclazide metformin+ gliclazide GlaxoSmithKline marketed Antidiabetic combination (biguanide + sulfonylurea) Metformin: mitochondrial glycerophosphate dehydrogenase; Gliclazide: ATP-sensitive potassium channels on pancreatic beta cells
medical nutrition therapy + metformin medical nutrition therapy + metformin Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes marketed Combination therapy: dietary intervention + biguanide antidiabetic AMP-activated protein kinase (AMPK) and hepatic glucose metabolism (metformin component)
Linagliptin / Metformin Oral Tablet Linagliptin / Metformin Oral Tablet Universidad de Guanajuato marketed DPP-4 inhibitor / Biguanide combination DPP-4 (dipeptidyl peptidase-4) / AMPK pathway
MET + Vildagliptin Group MET + Vildagliptin Group Hospital de Clinicas de Porto Alegre marketed Combination antidiabetic agent (biguanide + DPP-4 inhibitor) Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)
SGLT2i+Metformin+Cofrogliptin SGLT2i+Metformin+Cofrogliptin Huazhong University of Science and Technology marketed SGLT2 inhibitor + Biguanide + DPP-4 inhibitor (fixed-dose combination) SGLT2, mitochondrial complex I, DPP-4
oral hypoglycemic agents oral hypoglycemic agents Queen Elizabeth II Health Sciences Centre marketed Oral hypoglycemic agents (multiple classes: sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

  1. AstraZeneca · 4 drugs in this class
  2. Merck Sharp & Dohme LLC · 3 drugs in this class
  3. University of Texas Southwestern Medical Center · 2 drugs in this class
  4. Mount Sinai Hospital, Canada · 2 drugs in this class
  5. GlaxoSmithKline · 2 drugs in this class
  6. Eli Lilly and Company · 2 drugs in this class
  7. University Magna Graecia · 2 drugs in this class
  8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
  9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
  10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). metformin 0.85 twice daily for 6 months — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-0-85-twice-daily-for-6-months. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: